Ophthalmic composition containing ripeprost

By adjusting the pH value and using yedic acid or its salt, combined with nonionic isotonic agents, the problem of unstable sperprost at high temperatures is solved, the preservation effect and stability of ophthalmic compositions are improved, and the Long-term stability and effectiveness at high temperatures.

CN119072313APending Publication Date: 2024-12-03SANTEN PHARMACEUTICAL CO LTD +1
View PDF 8 Cites 0 Cited by

Patent Information

Application Number
CN202380035554.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-04-22
Filing Date
2023-04-21
Publication Date
2024-12-03

AI Technical Summary

Technical Problem

The ophthalmic compositions containing sperprost in the prior art are unstable at high temperatures, and their storage efficacy is affected by the type of isotonic agents, and there is a lack of effective stabilization and preservation methods.

Method used

By adjusting the pH value to the range of 5 to 8, combining edelic acid or its salt, and using nonionic isotonic agents to improve the stability and preservation effect of sepelprost, an appropriate sterilization method is selected to maintain the composition. stability.

Benefits of technology

Maintain the stability of sperprost at high temperatures, and improve the preservation effect of ophthalmic compositions through appropriate isotonic agents and sterilization methods to ensure the long-term stability and effectiveness of the composition.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119072313A_ABST
    Figure CN119072313A_ABST
Patent Text Reader

Abstract

The purpose of the present invention is to discover a method for stabilizing an ophthalmic composition containing ripeprost, and more specifically, to discover a method for stably maintaining ripeprost even at high temperatures, and to discover a method for maintaining the storage efficacy of the ophthalmic composition. The present invention relates to an ophthalmic composition which contains ripeprost at a concentration of 0.0001 to 0.003% (w / v) and has a pH in the range of 5 to 8.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to an ophthalmic composition containing spepprostil (hereinafter, also referred to as the ophthalmic composition of the present invention). Background Art

[0002] Glaucoma is an incurable eye disease that is dangerous enough to cause blindness due to increased intraocular pressure caused by various causes, damage to the internal tissues of the eyeball (retina, optic nerve, etc.). As a treatment for glaucoma, there is usually intraocular pressure reduction therapy, and its representative ones include drug therapy, laser therapy, surgical therapy, etc.

[0003] Drug therapy includes sympathomimetics (non-selective stimulants such as dipivefrin, α2 receptor agonists such as brimonidine), sympathetic nerve blockers (β-blockers such as timolol, benfuranolol, carteolol, nipradilol, betaxolol, levobunolol, metipranolol, α1 receptor blockers such as bunazosin hydrochloride), parasympathomimetic drugs (pilocarpine, etc.), carbonic anhydrase inhibitors (acetazolamide, etc.), prostaglandins (isopropyl unoprostone, latanoprost, travoprost, bimatoprost, etc.), Rho kinase inhibitors (rosudil), and the like.

[0004] Here, sepetaprost is a compound represented by formula (1),

[0005] [Chemical formula 1]

[0006]

[0007] It is described as one of a large number of compounds in Patent Documents 1 and 2. It is also described that the compound has a strong and sustained intraocular pressure lowering effect and is therefore useful as a therapeutic agent for glaucoma (Non-Patent Document 1).

[0008] In addition, it has been reported that in order to obtain a more powerful effect of reducing intraocular pressure, Spepprost is used in combination with other medicaments having an intraocular pressure reducing effect. For example, in patent documentation 3, a combined administration of Spepprost and a beta blocker has been reported, in patent documentation 4, a combined administration of Spepprost and a Rho kinase inhibitor has been reported, and in patent documentation 5, a combined administration of Spepprost and an EP2 agonist has been reported. In addition, it has been reported that a pharmaceutical preparation for treating or preventing glaucoma or ocular hypertension containing Spepprost as an effective ingredient is administered to a patient with insufficient effects of other glaucoma or ocular hypertension therapeutic drugs (patent documentation 6). In addition, a pharmaceutical composition (patent documentation 7) comprising Spepprost, for the treatment of myopia, myopia prevention and / or the inhibition of myopia development has also been reported.

[0009] However, there has been no report on any study of the stability and storage efficacy of ophthalmic compositions containing spepprostil.

[0010] Prior art literature

[0011] Patent Literature

[0012] Patent Document 1: International Publication No. 2011 / 013651

[0013] Patent Document 2: International Publication No. 2012 / 102357

[0014] Patent Document 3: International Publication No. 2019 / 124523

[0015] Patent Document 4: International Publication No. 2019 / 124488

[0016] Patent Document 5: International Publication No. 2019 / 124489

[0017] Patent Document 6: International Publication No. 2022 / 034909

[0018] Patent Document 7: International Publication No. 2021 / 145356

[0019] Non-patent literature

[0020] Non-patent literature 1: Invest Ophthalmol Vis Sci. 2015Apr; 56(4): 2547-52 Summary of the invention

[0021] Technical problem solved by the invention

[0022] The present inventors have conducted various studies on ophthalmic compositions containing sepeprost and unexpectedly found that when the ophthalmic composition containing sepeprost is stored at high temperature, sepeprost becomes unstable. In addition, the present inventors unexpectedly found that the type of isotonic agent contained in the ophthalmic composition affects the storage efficacy.

[0023] Therefore, the technical problem to be solved by the present invention is to find a method for stabilizing an ophthalmic composition containing sepeprost, more specifically, to find a method for stably maintaining sepeprost even at high temperatures (e.g., 70° C.), and to find a method for maintaining the preservation efficacy of the ophthalmic composition.

[0024] Technical means of solving problems

[0025] The present inventors have conducted intensive studies to solve the above problems and have found that the stability of sepeprost can be improved by adjusting the pH of the ophthalmic composition containing sepeprost to 5 to 8, and that the stability of sepeprost can be further improved by adding edetic acid or a salt thereof, thereby completing the present invention.

[0026] In addition, the present inventors unexpectedly found that the preservation efficacy can be improved when an ionic isotonic agent is added to an ophthalmic composition. On the other hand, in the presence of benzalkonium chloride, the preservation efficacy is reduced by adding an ionic isotonic agent, and the preservation efficacy can be maintained by adding a nonionic isotonic agent. In addition, the present inventors found that the preservation stability of sepeprost in the ophthalmic composition can be maintained at a high level by selecting a sterilization method for the ophthalmic composition containing sepeprost.

[0027] That is, the present invention provides the following contents.

[0028] [1] An ophthalmic composition comprising spepprostil at a concentration of 0.0001 to 0.003% (w / v) and having a pH in the range of 5 to 8.

[0029] [2] The ophthalmic composition according to [1], further comprising edetic acid or a salt thereof at a concentration exceeding 0.01% (w / v).

[0030] [3] The ophthalmic composition according to [2], wherein

[0031] The concentration of edetic acid or its salt is 0.05% (w / v) or more.

[0032] [4] The ophthalmic composition according to [2], wherein

[0033] The concentration of edetic acid or its salt is 0.05 to 0.5% (w / v).

[0034] [5] The ophthalmic composition according to [2], wherein

[0035] The concentration of edetic acid or its salt is 0.05 to 0.2% (w / v).

[0036] [6] The ophthalmic composition according to any one of [1] to [5], wherein the pH thereof is within the range of 6 to 7.

[0037] [7] The ophthalmic composition according to any one of [1] to [5], wherein the pH is 6.5.

[0038] [8] The ophthalmic composition according to any one of [1] to [7], further comprising an isotonicity agent.

[0039] [9] The ophthalmic composition according to [8], wherein

[0040] The isotonic agent is an ionic isotonic agent.

[0041]

[10] The ophthalmic composition according to [9], which does not contain benzalkonium chloride.

[0042]

[11] The ophthalmic composition according to [9], which does not contain a preservative.

[0043]

[12] The ophthalmic composition according to any one of [9] to

[11] , which does not contain a nonionic isotonicity agent.

[0044]

[13] The ophthalmic composition according to [8], wherein

[0045] The isotonic agent is a non-ionic isotonic agent.

[0046]

[14] The ophthalmic composition according to

[13] , further comprising benzalkonium chloride.

[0047]

[15] The ophthalmic composition according to

[13] or

[14] , which does not contain an ionic isotonic agent.

[0048]

[16] An ophthalmic composition comprising spepprostil at a concentration of 0.0001 to 0.003% (w / v), a nonionic isotonic agent, and benzalkonium chloride, and having a pH in the range of 5 to 8.

[0049]

[17] The ophthalmic composition according to

[16] , which does not contain an ionic isotonic agent.

[0050]

[18] An ophthalmic composition comprising an ionic isotonic agent and 0.0001 to 0.003% (w / v) of spepprostil, does not contain benzalkonium chloride, and has a pH in the range of 5 to 8.

[0051]

[19] The ophthalmic composition according to

[18] , which does not contain a preservative.

[0052]

[20] An ophthalmic composition comprising:

[0053] 0.0001 to 0.003% (w / v) of sepeprost,

[0054] Edetic acid or a salt thereof at a concentration exceeding 0.01% (w / v), and

[0055] Ionic isotonic agents,

[0056] The ophthalmic composition does not contain a nonionic isotonic agent and benzalkonium chloride,

[0057] The pH of the ophthalmic composition is in the range of 5-8.

[0058]

[21] An ophthalmic composition comprising:

[0059] 0.0001 to 0.003% (w / v) of sepeprost,

[0060] Edetic acid or a salt thereof at a concentration exceeding 0.01% (w / v), and

[0061] Nonionic isotonic agents and benzalkonium chloride,

[0062] The ophthalmic composition does not contain an ionic isotonic agent,

[0063] The pH of the ophthalmic composition is in the range of 5-8.

[0064]

[22] The ophthalmic composition according to any one of

[12] to

[17] ,

[20] and

[21] , wherein

[0065] The nonionic isotonic agent is at least one selected from the group consisting of mannitol, glycerol, propylene glycol, polyethylene glycol, sorbitol, trehalose, maltose and sucrose.

[0066]

[23] The ophthalmic composition according to

[22] , wherein

[0067] The non-ionic isotonic agent is mannitol.

[0068]

[24] The ophthalmic composition according to any one of [9] to

[12] ,

[15] and

[17] to

[23] , wherein

[0069] The ionic isotonic agent is at least one selected from the group consisting of sodium chloride, potassium chloride, calcium chloride and magnesium chloride.

[0070]

[25] The ophthalmic composition according to

[24] , wherein

[0071] The ionic isotonic agent is sodium chloride.

[0072]

[26] The ophthalmic composition according to any one of [1] to

[25] , further comprising a buffer.

[0073]

[27] The ophthalmic composition according to any one of [1] to

[26] , further comprising a surfactant.

[0074]

[28] The ophthalmic composition according to any one of [1] to

[27] , which is a sterilized ophthalmic composition.

[0075]

[29] The ophthalmic composition according to

[28] , wherein

[0076] Sterilization is filter filtration sterilization.

[0077]

[30] An ophthalmic composition comprising:

[0078] 0.0001 to 0.003% (w / v) of sepeprost,

[0079] 0.05-0.3% (w / v) concentration of polysorbate 80,

[0080] Sodium citrate hydrate at a concentration of 0.1 to 0.5% (w / v),

[0081] 0.05 to 0.5% (w / v) of edetate sodium, and

[0082] 0.5~1% (w / v) concentration of sodium chloride,

[0083] The ophthalmic composition does not contain benzalkonium chloride,

[0084] The pH of the ophthalmic composition is 6-7.

[0085]

[31] An ophthalmic composition comprising:

[0086] 0.0001 to 0.003% (w / v) of sepeprost,

[0087] 0.05-0.3% (w / v) concentration of polysorbate 80,

[0088] Sodium citrate hydrate at a concentration of 0.1 to 0.5% (w / v),

[0089] 0.05-0.5% (w / v) concentration of edetate sodium,

[0090] 1-6% (w / v) concentration of mannitol, and

[0091] Benzalkonium chloride at a concentration of 0.001 to 0.0075% (w / v),

[0092] The pH of the ophthalmic composition is 6-7.

[0093]

[32] An ophthalmic composition comprising:

[0094] 0.0001 to 0.003% (w / v) of sepeprost,

[0095] 0.05-0.3% (w / v) concentration of polysorbate 80,

[0096] Sodium citrate hydrate at a concentration of 0.1 to 0.5% (w / v),

[0097] 0.05 to 0.5% (w / v) of edetate sodium, and

[0098] 0.5~1% (w / v) concentration of sodium chloride,

[0099] The ophthalmic composition does not contain benzalkonium chloride,

[0100] The pH of the ophthalmic composition is 6.5.

[0101]

[33] An ophthalmic composition comprising:

[0102] 0.0001 to 0.003% (w / v) of sepeprost,

[0103] 0.05-0.3% (w / v) concentration of polysorbate 80,

[0104] Sodium citrate hydrate at a concentration of 0.1 to 0.5% (w / v),

[0105] 0.05-0.5% (w / v) concentration of edetate sodium,

[0106] 1-6% (w / v) concentration of mannitol, and

[0107] Benzalkonium chloride at a concentration of 0.001 to 0.0075% (w / v),

[0108] The pH of the ophthalmic composition is 6.5.

[0109]

[34] The ophthalmic composition according to any one of [1] to

[33] , wherein

[0110] The concentration of sepeprost is 0.001 to 0.003% (w / v).

[0111]

[35] The ophthalmic composition according to any one of [1] to

[33] , wherein

[0112] The concentration of sepeprost is 0.002-0.003% (w / v).

[0113]

[36] The ophthalmic composition according to any one of [1] to

[33] , wherein

[0114] The concentration of sepeprost was 0.002% (w / v).

[0115]

[37] An ophthalmic composition comprising spepprostil at a concentration of 0.002 to 0.003% (w / v) and having a pH in the range of 6 to 7.

[0116]

[38] An ophthalmic composition comprising spepprostil at a concentration of 0.002% (w / v) and having a pH in the range of 6 to 7.

[0117]

[39] The ophthalmic composition according to any one of [1] to

[38] , wherein

[0118] The ophthalmic composition is an eye drop.

[0119]

[40] The ophthalmic composition according to any one of [1] to

[39] , contained in a unit dose eye drop container.

[0120]

[41] The ophthalmic composition according to any one of [1] to

[39] , which is contained in a multi-dose eye drop container.

[0121]

[42] The ophthalmic composition according to any one of [1] to

[41] , which is contained in a plastic eye drop container.

[0122]

[43] The ophthalmic composition according to any one of [1] to

[42] , which is used for preventing or treating glaucoma or ocular hypertension.

[0123] In addition, the present invention also relates to the following contents.

[0124]

[44] A method for stabilizing spepprostil in an ophthalmic composition, wherein:

[0125] In the ophthalmic composition containing spepprostil at a concentration of 0.0001 to 0.003% (w / v), the pH is adjusted to a range of 5 to 8.

[0126]

[45] The method according to

[44] , wherein:

[0127] In the ophthalmic composition containing spepprostil at a concentration of 0.002 to 0.003% (w / v), the pH is adjusted to a range of 6 to 7.

[0128]

[46] The method according to

[44] or

[45] , wherein:

[0129] In the ophthalmic composition containing spepprostil at a concentration of 0.002% (w / v), the pH is adjusted to a range of 6 to 7.

[0130]

[47] A method for stabilizing an ophthalmic composition containing spepprostil, comprising adding edetic acid or a salt thereof at a concentration exceeding 0.01% (w / v) and adjusting the pH to a range of 5 to 8.

[0131]

[48] ​​A method for imparting a preservative effect to an ophthalmic composition containing spepprostil, comprising adding an ionic isotonic agent.

[0132]

[49] A method for imparting a preservative effect to an ophthalmic composition containing spepprostil, comprising adding a nonionic isotonicity agent and benzalkonium chloride.

[0133]

[50] A method for stabilizing sepeprost in the ophthalmic composition, comprising the step of sterilizing the ophthalmic composition containing sepeprost.

[0134]

[51] The method according to

[50] , wherein:

[0135] Sterilization is filter filtration sterilization.

[0136]

[52] A method for suppressing a decrease in the content of sepeprost in the ophthalmic composition, comprising the step of subjecting the ophthalmic composition containing sepeprost to a filter sterilization treatment.

[0137]

[53] A method for stabilizing spepprostil in the ophthalmic composition, comprising the step of placing the ophthalmic composition according to any one of [1] to

[43] in a plastic eye drop container.

[0138]

[54] An ophthalmic pharmaceutical product, wherein:

[0139] The ophthalmic composition according to any one of [1] to

[43] is contained in a unit-dose eye drop container or a multi-dose eye drop container.

[0140]

[55] An ophthalmic pharmaceutical product, wherein:

[0141] The ophthalmic composition according to any one of [1] to

[43] is contained in a plastic eye drop container.

[0142]

[56] A method for producing an ophthalmic pharmaceutical product, comprising the step of sterilizing the ophthalmic composition according to any one of [1] to

[43] .

[0143]

[57] The manufacturing method according to

[56] , wherein:

[0144] Sterilization is filter filtration sterilization.

[0145]

[58] The production method according to

[56] or

[57] , further comprising the step of placing the sterilized ophthalmic composition in an eye drop container.

[0146]

[59] The manufacturing method according to

[56] to

[58] , wherein

[0147] The eye drop container is a plastic eye drop container.

[0148]

[60] The manufacturing method according to

[56] to

[59] , wherein

[0149] The eye drop container is a unit-dose eye drop container or a multi-dose eye drop container.

[0150] It should be noted that any two or more of the technical solutions [1] to

[60] may be selected and combined.

[0151] Effects of the Invention

[0152] According to the present invention, the stability of Spepprostil in an ophthalmic composition can be improved, and an ophthalmic composition that can maintain its stability even when exposed to high temperatures during the circulation process and storage process can be provided. In addition, in the present invention, not only the stability of Spepprostil can be maintained, but also an ophthalmic composition that can maintain the preservation efficacy by using an isotonic agent of an appropriate type can be provided. In addition, in the present invention, an ophthalmic composition that can maintain the higher preservation stability of Spepprostil in an ophthalmic composition by selecting a sterilization method for an ophthalmic composition containing Spepprostil can be provided. BRIEF DESCRIPTION OF THE DRAWINGS

[0153] [ Figure 1 ] Figure 1 This is a graph showing the test results in Test Example 1.

[0154] [ Figure 2 ] Figure 2 This is a graph showing the test results in Test Example 2.

[0155] [ Figure 3 ] Figure 3 These are photographs showing the test results in Test Example 4. DETAILED DESCRIPTION

[0156] Hereinafter, the present invention will be described in detail.

[0157] In the present invention, Spepprostil is a compound represented by the following formula (1) (CAS registration number: 1262873-06-2):

[0158] [Chemical formula 2]

[0159]

[0160] Also known as 2-propyl 4-{(3S,5aR,6R,7R,8aS)-6-[(1E,3R)-4-(2,5-difluorophenoxy)-3-hydroxy-1-buten-1-yl]-7-hydroxyoctahydro-2H-cyclopenta[b]oxepin-3-yl}butyrate or ONO-9054.

[0161] Spepprostil can be produced according to the methods described in International Publication No. 2011 / 013651 (Patent Document 1) and International Publication No. 2018 / 003945, or a common method in the technical field.

[0162] When there are geometric isomers and / or optical isomers in sepeprost, the isomers are also included in the scope of the present invention.

[0163] When there is proton tautomerism in sepeprost, the present invention also includes its tautomer (keto form, enol form).

[0164] When there are polymorphs and / or polymorph groups (polymorph systems) in Spepprostil, the present invention also includes its polymorphs and / or polymorph groups (polymorph systems). Here, the polymorph group (polymorph system) refers to the crystal form and / or its entirety in each stage under various changes of the crystal form under the conditions and / or state of the manufacture, crystallization, storage, etc. of the crystal (it should be noted that this state also includes the state of formulation).

[0165] Spepprostil can be in the form of a hydrate or a solvate.

[0166] In the ophthalmic composition of the present invention, the content of sepeprost is 0.0001 to 0.003% (w / v). The lower limit of the content of sepeprost is preferably 0.0001% (w / v) or more, more preferably 0.0003% (w / v) or more, further preferably 0.001% (w / v) or more, and further preferably 0.0015% (w / v) or more, and the upper limit is preferably 0.003% (w / v) or less, more preferably 0.0025% (w / v) or less, and further preferably 0.002% (w / v) or less. In more detail, the content can be within the range of any combination of the lower limit and the upper limit, for example, the range of 0.0001 to 0.003% (w / v), 0.0003 to 0.003% (w / v), 0.0015 to 0.003% (w / v), 0.001 to 0.003% (w / v), 0.002 to 0.003% (w / v), 0.0001 to 0.025% (w / v), 0.0003 to 0.025% (w / v), 0.0015 to 0.025% (w / v), 0.001 to 0.025% (w / v), 0.0001 to 0.002% (w / v), 0.0003 to 0.002% (w / v), and 0.001 to 0.002% (w / v). In addition, more specifically, as preferred content, for example, 0.001% (w / v), 0.002% (w / v), and 0.003% (w / v) can be cited, among which 0.002% (w / v) is preferred. In addition, the content can also be set as a preferred content in the case where the ophthalmic composition is an eye drop, for example. Here, "% (w / v)" refers to the mass (g) of the active ingredient (sepprostil) and additives contained in 100 mL of the ophthalmic composition. For example, 0.001% (w / v) of sepprostil means that the content of sepprostil contained in 100 mL of the ophthalmic composition is 0.001g. It should be noted that in this specification, numerical values ​​(such as content, concentration, pH, etc.) may be accompanied by the term "about", in which case, it refers to a range of ±10% containing the value. For example, "about 10" means including "9 to 11". "About" involving a numerical range expressed using "~" applies to both ends of its range. Thus, for example, "about 10 to 20" means "9 to 22."

[0167] It should be noted that, when sepeprost is in the form of a hydrate or a solvate, the content of sepeprost can be calculated based on any of the free form, hydrate and solvate of sepeprost. The same applies to the contents of other components.

[0168] The ophthalmic composition of the present invention may contain, for example, edetic acid or a salt thereof.

[0169] As edetic acid or its salt in the present invention, for example, edetic acid (ethylenediaminetetraacetic acid), edetic acid monosodium, edetic acid disodium, edetic acid trisodium, edetic acid tetrasodium etc. can be mentioned, and it can be a hydrate thereof. Among them, in the present invention, edetic acid disodium (hereinafter also referred to as edetic acid sodium) can be used most preferably.

[0170] In the ophthalmic composition of the present invention, the content of edetic acid or its salt exceeds 0.01% (w / v). As the lower limit of edetic acid or its salt, for example, preferably 0.05% (w / v) or more, more preferably 0.1% (w / v) or more, more preferably 0.1% (w / v) or more, and as the upper limit, for example, preferably 0.5% (w / v) or less, more preferably 0.3% (w / v) or less, 0.2% (w / v) or less. In more detail, the content can be within the range of any combination of the lower limit and the upper limit, for example, 0.05-0.5% (w / v), more than 0.05% (w / v) and less than 0.5% (w / v), 0.05-0.2% (w / v), more than 0.05% (w / v) and less than 0.2% (w / v), 0.1-0.3% (w / v), more than 0.1% (w / v) and less than 0.3% (w / v), 0.1-0.2% (w / v), more than 0.1% (w / v) and less than 0.2% (w / v). In addition, more specifically, preferred contents include, for example, 0.11% (w / v), 0.12% (w / v), 0.13% (w / v), 0.14% (w / v), 0.15% (w / v), 0.16% (w / v), 0.17% (w / v), 0.18% (w / v), 0.19% (w / v), and 0.2% (w / v).

[0171] In the ophthalmic composition of the present invention, the pH is in the range of 5 to 8. A more preferred pH range is 5.5 to 7.5, and a further preferred pH range is 6 to 7. In addition, more specifically, preferred pH values ​​include, for example, 6.0, 6.1, 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.8, 6.9, and 7.0, with pH 6.5 being preferred. The pH of the ophthalmic composition can be adjusted, for example, by adding an appropriate amount of a pH adjuster described below.

[0172] In addition, additives may be used as needed in the ophthalmic composition of the present invention. As additives, for example, isotonic agents, preservatives, buffers, surfactants, stabilizers, antioxidants, pH regulators, bases, etc. may be added. These may be used alone, or two or more may be used in combination, and may be mixed in appropriate amounts.

[0173] Examples of the isotonic agent that can be incorporated into the ophthalmic composition of the present invention include ionic isotonic agents and nonionic isotonic agents.

[0174] Examples of the ionic isotonic agent include sodium chloride, potassium chloride, calcium chloride, and magnesium chloride. Among them, sodium chloride is preferred.

[0175] Examples of the nonionic isotonic agent include mannitol, glycerol, propylene glycol, polyethylene glycol, sorbitol, trehalose, maltose, and sucrose. Among them, mannitol (preferably D-mannitol) is preferred.

[0176] When an isotonic agent is added to the ophthalmic composition of the present invention, the isotonic agent may be used alone or in combination of two or more components. In addition, for example, when the ophthalmic composition of the present invention contains an ionic isotonic agent, a nonionic isotonic agent may not be contained, and only an ionic isotonic agent may be contained as an isotonic agent. When the ophthalmic composition of the present invention contains a nonionic isotonic agent, an ionic isotonic agent may not be contained, and only a nonionic isotonic agent may be contained as an isotonic agent.

[0177] In the present invention, when an ionic isotonic agent is added to an ophthalmic composition, as shown in the examples below, it can impart a preservative effect to the ophthalmic composition. Therefore, an ionic isotonic agent is preferably added to the ophthalmic composition of the present invention. In addition, the ophthalmic composition of the present invention may optionally contain a preservative such as benzalkonium chloride. When the ophthalmic composition contains an ionic isotonic agent, it is preferably not added with a preservative such as benzalkonium chloride.

[0178] In the present invention, the nonionic isotonic agent is as follows, and is preferably blended when the ophthalmic composition of the present invention contains benzalkonium chloride as a preservative.

[0179] When an isotonic agent is added to the ophthalmic composition of the present invention, the content of the isotonic agent can be appropriately adjusted depending on the type of the isotonic agent, etc., and is preferably 0.001 to 20% (w / v), more preferably 0.01 to 15% (w / v), and further preferably 0.1 to 10% (w / v).

[0180] More specifically, when the isotonic agent to be used is an ionic isotonic agent, the content of the ionic isotonic agent is preferably 0.001 to 10% (w / v), more preferably 0.01 to 5% (w / v), and even more preferably 0.5 to 1% (w / v). In addition, further specific preferred contents include, for example, 0.5% (w / v), 0.55% (w / v), 0.6% (w / v), 0.65% (w / v), 0.7% (w / v), 0.75% (w / v), 0.8% (w / v), 0.85% (w / v), 0.9% (w / v), 0.95% (w / v), and 1% (w / v).

[0181] More specifically, when the isotonic agent used is a nonionic isotonic agent, the content of the nonionic isotonic agent is preferably 0.01 to 20% (w / v), more preferably 0.5 to 10% (w / v), and even more preferably 1 to 6% (w / v). In addition, further specific preferred contents include, for example, 1% (w / v), 2% (w / v), 3% (w / v), 4% (w / v), 5% (w / v), and 6% (w / v).

[0182] Examples of the preservative that can be incorporated into the ophthalmic composition of the present invention include inverse soaps, parabens, alcohols, and organic acids or salts thereof.

[0183] As the inverse soaps, for example, benzalkonium chloride (also called benzalkonium chloride), benzalkonium bromide (also called benzalkonium bromide), benzophenone chloride (also called benzethonium chloride, Benzethonium Chloride), benzophenone bromide (also called benzethonium bromide, Benzethonium Bromide), chlorhexidine or its salts, etc. can be cited. It should be noted that when the ophthalmic composition of the present invention contains benzalkonium chloride as a preservative, when an ionic isotonic agent is combined, as shown in the examples below, the preservation efficacy is reduced. Therefore, when the ophthalmic composition of the present invention contains benzalkonium chloride, it is preferably not containing an ionic isotonic agent. In addition, when the ophthalmic composition of the present invention contains benzalkonium chloride, it is preferably combined with a nonionic isotonic agent as an isotonic agent.

[0184] Examples of the parabens include methyl paraben, ethyl paraben, propyl paraben, butyl paraben and the like.

[0185] Examples of the alcohols include chlorobutanol and the like.

[0186] Examples of the organic acid or its salt include sorbic acid or its salt, and examples of the sorbic acid or its salt include sodium sorbate and potassium sorbate.

[0187] When a preservative is added to the ophthalmic composition of the present invention, one preservative may be used alone, or two or more preservatives may be used in combination. It should be noted that the ophthalmic composition of the present invention may not contain a preservative, in which case it is preferred that an ionic isotonic agent be contained as the isotonic agent, and a nonionic isotonic agent be not contained.

[0188] The content of the preservative in the case of adding a preservative to the ophthalmic composition of the present invention can be appropriately adjusted according to the type of the preservative, etc., and is preferably 0.00001 to 1% (w / v), more preferably 0.0001 to 0.1% (w / v), more preferably 0.0005 to 0.01% (w / v), and most preferably 0.001 to 0.0075% (w / v). In addition, more specifically, for example, preferably 0.001% (w / v), 0.002% (w / v), 0.003% (w / v), 0.004% (w / v), 0.005% (w / v), 0.006% (w / v), 0.007% (w / v), 0.0075% (w / v).

[0189] Examples of buffers that can be incorporated into the ophthalmic composition of the present invention include phosphoric acid or its salts, boric acid or its salts, citric acid or its salts, acetic acid or its salts, carbonic acid or its salts, tartaric acid or its salts, ε-aminocaproic acid, tromethamine, etc. Among them, phosphoric acid or its salts and citric acid or its salts are preferred, and citric acid or its salts are more preferred. It should be noted that these also include hydrates.

[0190] Examples of the phosphoric acid or a salt thereof include phosphoric acid, sodium phosphate, sodium dihydrogen phosphate, disodium hydrogen phosphate, potassium phosphate, potassium dihydrogen phosphate, and dipotassium hydrogen phosphate.

[0191] Examples of the boric acid or a salt thereof include boric acid, sodium borate, potassium borate, and the like.

[0192] Examples of citric acid or a salt thereof include citric acid, sodium citrate, and disodium citrate. Among them, sodium citrate can be preferably used.

[0193] Examples of acetic acid or a salt thereof include acetic acid, sodium acetate, potassium acetate, and the like.

[0194] Examples of carbonic acid or a salt thereof include sodium carbonate and sodium hydrogen carbonate.

[0195] Examples of tartaric acid or a salt thereof include tartaric acid, sodium tartrate, potassium tartrate, and the like.

[0196] When a buffer is blended in the ophthalmic composition of the present invention, the buffer may be used alone or in combination of two or more components.

[0197] The content of the buffer in the case of adding a buffer to the ophthalmic composition of the present invention can be appropriately adjusted depending on the type of the buffer, etc., and is preferably 0.001 to 10% (w / v), more preferably 0.01 to 5% (w / v), and even more preferably 0.1 to 0.5% (w / v). In addition, more specifically, for example, 0.1% (w / v), 0.2% (w / v), 0.3% (w / v), 0.4% (w / v), and 0.5% (w / v) are preferred.

[0198] Examples of the surfactant that can be incorporated into the ophthalmic composition of the present invention include cationic surfactants, anionic surfactants, and nonionic surfactants. Among them, nonionic surfactants are preferred.

[0199] Examples of the cationic surfactant include alkylamine salts, alkylamine polyoxyethylene adducts, fatty acid triethanolamine monoester salts, acylaminoethyldiethylamine salts, fatty acid polyamine condensates, alkylimidazolines, 1-acylaminoethyl-2-alkylimidazolines, and 1-hydroxyethyl-2-alkylimidazolines.

[0200] Examples of the anionic surfactant include phospholipids such as lecithin.

[0201] Examples of the nonionic surfactant include polyoxyethylene fatty acid esters such as polyoxyl 40 stearate; polyoxyethylene sorbitan fatty acid esters such as polysorbate 80, polysorbate 60, polysorbate 40, polyoxyethylene sorbitan monolaurate, polyoxyethylene sorbitan trioleate, and polysorbate 65; polyoxyethylene hydrogenated castor oils such as polyoxyethylene hydrogenated castor oil 10, polyoxyethylene hydrogenated castor oil 40, polyoxyethylene hydrogenated castor oil 50, and polyoxyethylene hydrogenated castor oil 60; polyoxyethylene 5 castor oil, polyoxyethylene 9 castor oil, and polyoxyethylene 100 castor oil. Polyoxyethylene castor oils such as polyoxyethylene (15) castor oil, polyoxyethylene (35) castor oil, and polyoxyethylene (40) castor oil; polyoxyethylene (160) polyoxypropylene (30) glycol, polyoxyethylene (42) polyoxypropylene (67) glycol, polyoxyethylene (54) polyoxypropylene (39) glycol, polyoxyethylene (196) polyoxypropylene (67) glycol, and polyoxyethylene (20) polyoxypropylene (20) glycol; sucrose fatty acid esters such as sucrose stearate; tocopherol polyethylene glycol 1000 succinate (vitamin E TP GS), etc. Among them, polyoxyethylene sorbitan fatty acid esters are preferred, and polysorbate 80 is more preferred.

[0202] When a surfactant is blended in the ophthalmic composition of the present invention, the surfactant may be used alone or in combination of two or more components.

[0203] The content of the surfactant in the case of adding a surfactant to the ophthalmic composition of the present invention can be appropriately adjusted according to the type of the surfactant, etc., and is preferably 0.001 to 10% (w / v), more preferably 0.01 to 5% (w / v), further preferably 0.02 to 1% (w / v), and particularly preferably 0.05 to 0.3% (w / v). In addition, more specifically, for example, 0.05% (w / v), 0.1% (w / v), 0.2% (w / v), and 0.3% (w / v) are preferred.

[0204] Examples of the stabilizer that can be incorporated into the ophthalmic composition of the present invention include, in addition to the above-mentioned edetic acid or its salt, sulfites, monoethanolamine, cyclodextrin, dextran, taurine, and the like.

[0205] When a stabilizer is blended in the ophthalmic composition of the present invention, the stabilizer may be used alone or in combination of two or more components.

[0206] When a stabilizer is added in addition to edetic acid or a salt thereof in the ophthalmic composition of the present invention, the content of the stabilizer can be appropriately adjusted depending on the type of the stabilizer, etc., and is preferably 0.001 to 5% (w / v), more preferably 0.005 to 1% (w / v), and further preferably 0.01 to 0.5% (w / v).

[0207] Examples of the antioxidant that can be incorporated into the ophthalmic composition of the present invention include ascorbic acid, tocopherol, dibutylhydroxytoluene, sodium sulfite, and 2-mercaptobenzimidazole.

[0208] When an antioxidant is blended into the ophthalmic composition of the present invention, the antioxidant may be used alone or in combination of two or more components.

[0209] When an antioxidant is added to the ophthalmic composition of the present invention, the content of the antioxidant can be appropriately adjusted depending on the type of the antioxidant, etc., and is preferably 0.001 to 5% (w / v), more preferably 0.01 to 3% (w / v), and even more preferably 0.1 to 2% (w / v).

[0210] As pH adjusting agents that can be incorporated into the ophthalmic composition of the present invention, there are acids or bases. Examples of acids include hydrochloric acid, phosphoric acid, citric acid, acetic acid, and the like, and examples of bases include sodium hydroxide, potassium hydroxide, sodium carbonate, sodium bicarbonate, and the like. The pH of the ophthalmic composition of the present invention can be adjusted by appropriately adding these pH adjusting agents. Specifically, for example, the pH of the ophthalmic composition can be adjusted by appropriately adding hydrochloric acid and sodium hydroxide.

[0211] When a pH adjuster is blended into the ophthalmic composition of the present invention, the pH adjuster may be used alone or in combination of two or more components.

[0212] When the ophthalmic composition of the present invention is in the form of eye drops, water is preferably used as a base.

[0213] The osmotic pressure ratio of the ophthalmic composition of the present invention may be within the range allowed for ophthalmic preparations, and is, for example, 0.5 to 2.0, preferably 0.6 to 1.5, more preferably 0.7 to 1.2, and further preferably 0.9 to 1.1.

[0214] It should be noted that the osmotic pressure ratio is based on the 17th edition of the Japanese Pharmacopoeia, and is the ratio of the osmotic pressure of the sample relative to 286 mOs m (osmotic pressure of 0.9% (w / v) sodium chloride aqueous solution). The osmotic pressure can be measured with reference to the osmotic pressure measurement method (freezing point depression method) recorded in the Japanese Pharmacopoeia, and the standard solution for osmotic pressure ratio measurement (0.9% (w / v) sodium chloride aqueous solution) can be prepared by drying sodium chloride (Japanese Pharmacopoeia standard reagent) at 500-650°C for 40-50 minutes, cooling in a desiccator (silica gel), accurately weighing 0.900 g of it, dissolving it in pure water and accurately making it into 100 mL, or using a commercially available standard solution for osmotic pressure ratio measurement (0.9% (w / v) sodium chloride aqueous solution).

[0215] The ophthalmic composition of the present invention contains Spepprost as an effective ingredient, and is used for preventing or treating glaucoma or ocular hypertension, or for reducing intraocular pressure. As glaucoma in the present invention, primary open-angle glaucoma, secondary open-angle glaucoma, normal intraocular pressure glaucoma, aqueous humor oversecretion glaucoma, primary angle-closure glaucoma, secondary angle-closure glaucoma, plateau iris glaucoma, mixed glaucoma, developmental glaucoma, steroid glaucoma, exfoliation glaucoma, amyloid glaucoma, neovascular glaucoma, malignant glaucoma, crystalline capsule glaucoma, high fold iris syndrome (plateau iris syndrome) etc., preferably primary open-angle glaucoma, normal intraocular pressure glaucoma, primary angle-closure glaucoma. It should be noted that the ophthalmic composition of the present invention can contain an effective ingredient other than Spepprost, or can only contain Spepprost as the only effective ingredient.

[0216] The ophthalmic composition of the present invention can be administered orally or parenterally, for example, by eye drop administration, intravitreal administration, intraconjunctival sac administration, intracameral administration, subconjunctival administration, subTenon's fascia administration or lacrimal duct plug administration. The dosage form of the ophthalmic composition of the present invention includes eye drops, eye ointments, injections, lacrimal duct plugs, tablets, capsules, granules, powders, etc., and eye drops are particularly preferred.

[0217] The usage and dosage of the ophthalmic composition of the present invention are not particularly limited as long as they are sufficient to exert the desired medicinal effect, and can be appropriately selected according to the symptoms of the disease, the age and weight of the patient, the dosage form of the ophthalmic composition, and the like.

[0218] Specifically, in the case of eye drops, the amount per time is 1 to 5 drops, preferably 1 to 3 drops, more preferably 1 to 2 drops, and particularly preferably 1 drop, and 1 to 4 times a day, preferably 1 to 3 times a day, more preferably 1 to 2 times a day, particularly preferably once a day, and can be administered by eye drops every day to every week. Preferably, 1 drop is administered once a day, and eye drops are administered every day. Here, 1 drop is usually about 0.01 to about 0.1 mL, preferably about 0.015 to about 0.07 mL, and more preferably about 0.02 to about 0.05 mL.

[0219] In addition, the ophthalmic composition of the present invention is preferably an ophthalmic composition that has been sterilized. As the sterilization method of the ophthalmic composition, for example, electron beam (EB) sterilization, ethylene oxide gas (EOG) sterilization, hydrogen peroxide sterilization, gamma ray sterilization, filter filtration sterilization, high pressure steam (AC) sterilization, etc. can be mentioned. In the ophthalmic composition of the present invention, as the sterilization method of the ophthalmic composition, filter filtration sterilization is preferred.

[0220] In the present invention, "electron beam sterilization" or "EB sterilization" refers to a sterilization method that can sterilize using electron beams, and is not particularly limited to methods that use electron beams for sterilization. For example, the radiation dose can be appropriately selected between 1 and 100 kGy, and the irradiation time can be appropriately selected between a few seconds and a few minutes.

[0221] In the present invention, "ethylene oxide gas sterilization" or "EOG sterilization" refers to a sterilization method that can sterilize using ethylene oxide gas, and there is no particular limitation if the method uses ethylene oxide gas for sterilization. For example, the sterilization temperature is 30 to 60°C, the sterilization time is 1 to 10 hours, and the gas used can be only ethylene oxide gas or a mixed gas of ethylene oxide gas and carbon dioxide, etc., which can be appropriately selected.

[0222] In the present invention, "hydrogen peroxide sterilization" refers to a sterilization method that can kill bacteria using hydrogen peroxide, and is not particularly limited as long as it is a method for sterilization using hydrogen peroxide.

[0223] In the present invention, "gamma ray sterilization" refers to a sterilization method that can sterilize bacteria using gamma rays, and is not particularly limited as long as it is a method of sterilizing using gamma rays.

[0224] In the present invention, "filter sterilization" refers to a sterilization method that uses a membrane filter (for example, pore size 0.22 μm) to remove bacteria by filtration. The membrane filter can be made of PVDF (polyvinylidene fluoride), PES (polyether sulfone), PTFE (polytetrafluoroethylene), MCE (cellulose mixed ester) and other materials, and can have different pore sizes.

[0225] In the present invention, "high pressure steam (AC) sterilization" refers to a sterilization method that can sterilize using a high pressure steam sterilizer (autoclave), and there is no particular limitation if the method of sterilization using a high pressure steam sterilizer (autoclave) is used. For example, it is carried out at 115-118°C for 30 minutes, at 121-124°C for 15-20 minutes, or at 126-129°C for 10 minutes, and it is preferably carried out until the object reaches a sterile state.

[0226] The ophthalmic composition of the present invention can be filled into an airtight container for storage, for example, it can be filled, contained and stored in an eye drop container. As an eye drop container, from the viewpoint of material, for example, a resin (plastic) eye drop container can be cited. In addition, as an eye drop container, from the viewpoint of function, for example, a "multi-dose eye drop container" or a "unit dose eye drop container" can be cited.

[0227] In the present invention, a "multi-dose eye drop container" refers to an eye drop container having a container body and a lid that can be installed on the container body, and an eye drop container in which the lid can be freely unsealed and resealed. The multi-dose eye drop container usually contains multiple portions of eye drops (ophthalmic composition) for use for a certain period of time. In addition, when the ophthalmic composition of the present invention does not contain preservatives such as benzalkonium chloride, the ophthalmic composition can be contained in a PFMD (Preservative Free Multi Dose) container. In addition, the filling amount of the ophthalmic composition filled into the multi-dose eye drop container and the PFMD container is, for example, preferably 1 to 20 mL, more preferably 1 to 15 mL, further preferably 1 to 10 mL, further preferably 2.5 to 10 mL, and particularly preferably 5 mL.

[0228] On the other hand, a "unit-dose eye drop container" refers to an eye drop container that is sealed by welding at the bottle mouth, and is used for this purpose by breaking and unsealing the welded portion between the lid and the bottle-shaped body when in use. The unit-dose eye drop container contains eye drops (ophthalmic composition) for one or several uses. It should be noted that the eye drops contained in the unit-dose eye drop container usually do not contain preservatives such as benzalkonium chloride. In addition, the filling amount of the present composition filled in the unit-dose eye drop container is, for example, preferably 0.1 to 1 mL, more preferably 0.1 to 0.5 mL, further preferably 0.3 mL to 0.5 mL, and particularly preferably 0.3 mL or 0.4 mL.

[0229] In the present invention, as for the multi-dose eye drop container and the unit dose eye drop container, there is no particular restriction on the raw materials thereof, and various resins (plastics) can be used. As the resin that can be used, for example, polyethylene (PE), polypropylene (PP), polypropylene-polyethylene copolymer, polyethylene terephthalate (PET), polybutylene terephthalate (PBT), polyvinyl chloride, acrylic resin, polystyrene, etc. can be cited. Polyethylene is further classified by its density, and low-density polyethylene (LDPE), medium-density polyethylene (MDPE), high-density polyethylene (HDPE), etc. can be cited. In the present invention, polyethylene, polypropylene, propylene-ethylene copolymer, polyethylene terephthalate, etc. can be preferably used. Here, as for the propylene-ethylene copolymer, as long as it is a propylene polymer containing an ethylene component, it is not particularly limited, and preferably a propylene polymer containing an ethylene component of less than 10 mol%.

[0230] The eye drop container can be formed by one part or multiple parts, and can be any one of a one-piece eye drop container, a two-piece eye drop container or a three-piece eye drop container. It should be noted that, for example, when it is a three-piece eye drop container, it is formed by the three parts of the container body, the middle plug and the lid that hold the ophthalmic composition of the present invention, or an integrally formed container that is blow-molded and filled with liquid medicine at the same time is also included in the eye drop container according to its number of parts. In addition, when the container is formed by multiple parts, it can be formed by parts of the same raw material or by parts of different raw materials. In addition, it can be a part or all of the raw material components or the case of being coated. The container can be commercially available or manufactured by a known method.

[0231] One embodiment of the present invention is a method for stabilizing sepeprost in an ophthalmic composition containing sepeprost at a concentration of 0.0001 to 0.003% (w / v), by adjusting the pH to a range of 5 to 8. In the stabilization method of the present invention, the pH of the ophthalmic composition containing sepeprost at a concentration of 0.0001 to 0.003% (w / v) is adjusted to a range of 5 to 8. It should be noted that the detailed description of the ophthalmic composition of the present invention is also applicable to the stabilization method.

[0232] One embodiment of the present invention is a method for stabilizing an ophthalmic composition containing sepeprostil, comprising adding edetic acid or a salt thereof at a concentration exceeding 0.01% (w / v) to adjust the pH to a range of 5 to 8. In the stabilization method of the present invention, edetic acid or a salt thereof at a concentration exceeding 0.01% (w / v) is added to the ophthalmic composition containing sepeprostil to adjust the pH to a range of 5 to 8. It should be noted that the detailed description of the ophthalmic composition of the present invention is also applicable to the stabilization method.

[0233] One embodiment of the present invention is a method for imparting a preservative effect to an ophthalmic composition containing sepeprostil, wherein the method comprises an ionic isotonic agent. The method for imparting a preservative effect of the present invention is characterized in that an ionic isotonic agent is incorporated into the ophthalmic composition containing sepeprostil. It should be noted that the detailed description of the ophthalmic composition of the present invention is also applicable to the method for imparting a preservative effect.

[0234] One embodiment of the present invention is a method for imparting a preservative effect to an ophthalmic composition containing spepprostil, wherein the method comprises a nonionic isotonic agent and benzalkonium chloride. The method for imparting a preservative effect of the present invention is characterized in that a nonionic isotonic agent and benzalkonium chloride are blended in an ophthalmic composition containing spepprostil. It should be noted that the detailed description of the ophthalmic composition of the present invention is also applicable to the method for imparting a preservative effect.

[0235] One embodiment of the present invention is a method for stabilizing sepeprost in the ophthalmic composition, which comprises a step of sterilizing the ophthalmic composition containing sepeprost. The stabilization method of the present invention comprises a step of sterilizing the ophthalmic composition containing sepeprost. It should be noted that the detailed description of the ophthalmic composition of the present invention is also applicable to the stabilization method.

[0236] One embodiment of the present invention is a method for inhibiting the reduction of the content of sepeprostil in the ophthalmic composition, which comprises the step of sterilizing the ophthalmic composition containing sepeprostil by filtration. The method for inhibiting the reduction of the content of the present invention comprises the step of sterilizing the ophthalmic composition by filtration. It should be noted that the detailed description of the ophthalmic composition of the present invention is also applicable to the method for inhibiting the reduction of the content.

[0237] One embodiment of the present invention is a method for stabilizing the spepprostil in the ophthalmic composition, which comprises the step of containing the ophthalmic composition of the present invention in a plastic eye drop container. The stabilization method of the present invention comprises the step of containing the ophthalmic composition of the present invention in a plastic eye drop container. It should be noted that the detailed description of the ophthalmic composition of the present invention is also applicable to the stabilization method.

[0238] One embodiment of the present invention is an ophthalmic pharmaceutical product, characterized in that the ophthalmic composition of the present invention is contained in a unit-dose eye drop container or a multi-dose eye drop container. The ophthalmic pharmaceutical product of the present invention is characterized in that the ophthalmic composition of the present invention is contained in a unit-dose eye drop container or a multi-dose eye drop container. It should be noted that the detailed description of the ophthalmic composition of the present invention is also applicable to the ophthalmic pharmaceutical product.

[0239] One embodiment of the present invention is an ophthalmic pharmaceutical product, characterized in that the ophthalmic composition of the present invention is contained in a plastic eye drop container. The ophthalmic pharmaceutical product of the present invention is characterized in that the ophthalmic composition of the present invention is contained in a plastic eye drop container. It should be noted that the detailed description of the ophthalmic composition of the present invention is also applicable to the ophthalmic pharmaceutical product.

[0240] One embodiment of the present invention is a method for producing an ophthalmic pharmaceutical product, comprising the step of sterilizing the ophthalmic composition of the present invention. The production method of the present invention comprises the step of sterilizing the ophthalmic composition of the present invention. It should be noted that the detailed description of the ophthalmic composition of the present invention is also applicable to the production method.

[0241] Example

[0242] Hereinafter, the present invention will be described in detail with reference to test examples and preparation examples. These examples are used to better understand the present invention, but the scope of the present invention is not limited thereto.

[0243] [Test Example 1]

[0244] In the ophthalmic composition containing sepeprost, the effect of pH on the stability of sepeprost was investigated. In addition, the effect of sodium edetate on the stability of sepeprost was also investigated.

[0245] (1) Preparation of Test Preparations 1 to 4

[0246] By a common method in the art, test preparations 1 to 4 were prepared as shown in Table 1. Specifically, water for injection was added to 0.003 g of sepprostil, 0.3 g of sodium dihydrogen phosphate dihydrate, and 0.1 g of polysorbate 80 and stirred. An appropriate amount of sodium hydroxide or dilute hydrochloric acid was added as a pH adjuster to adjust the pH, and an appropriate amount of water for injection was added thereto to make the total amount 100 mL to prepare test preparation 1. Test preparations 2 to 4 were also prepared in the same manner as test preparation 1.

[0247] [Table 1]

[0248] Composition [% (w / v)] Test preparation 1 Test preparation 2 Test preparation 3 Test preparation 4 Spesprost 0.003 0.003 0.003 0.003 Sodium dihydrogen phosphate dihydrate 0.3 0.3 0.3 0.3 Polysorbate 80 0.1 0.1 0.1 0.1 Edetate Sodium - - - 0.12 Sodium hydroxide / dilute hydrochloric acid Moderate Moderate Moderate Moderate Water for injection Moderate Moderate Moderate Moderate pH 4.5 6.5 8.5 6.5

[0249] (2) Test methods

[0250] The test preparations 1 to 4 were filled into glass containers, respectively, and these test preparations were stored at 70° C. for up to 4 weeks. The concentration of sepeprost in the test preparations was measured by high performance liquid chromatography at the time points immediately before the start of storage and 1, 2, and 4 weeks after the start of storage. The concentration of sepeprost immediately before the start of storage was set as 100%, and the residual rate (%) of sepeprost was calculated.

[0251] (3) Test results and investigation

[0252] The test results are as follows Figure 1 As shown. Figure 1 As shown, the residual rate of sepeprost was significantly reduced in the test preparations 1 and 3 whose pH was adjusted to 4.5 or 8.5 due to storage at high temperature. In addition, the residual rate of sepeprost was reduced in the test preparation 2 (not containing sodium edetate) whose pH was adjusted to 6.5 after 2 weeks. On the other hand, the test preparation 2 showed a higher residual rate than the test preparations 1 and 3. Next, the test preparation 4 whose pH was adjusted to 6.5 and was combined with sodium edetate maintained a higher residual rate of sepeprost even after being stored at 70°C for 4 weeks. According to these results, it is shown that in the ophthalmic composition containing sepeprost, the stability of sepeprost is improved by adjusting the pH to 5 to 8, especially to pH 6.5. In addition, it is shown that the stability of sepeprost is further improved by combining edetic acid or its salt.

[0253] [Test Example 2]

[0254] In the ophthalmic composition containing sepeprost, the effect of the concentration of sodium edetate on the stability of sepeprost was investigated.

[0255] (1) Preparation of Test Preparations 5 to 9

[0256] Test preparations 5 to 9 were prepared as shown in Table 2 by the same method as for test preparation 1. Here, 0.000001% (w / v) of iron (III) nitrate was spiked into test preparations 5 to 9.

[0257] [Table 2]

[0258] Composition [% (w / v)] Test preparation 5 Test preparation 6 Test preparation 7 Tested preparation 8 Test preparation 9 Spesprost 0.002 0.002 0.002 0.002 0.002 Sodium Citrate Hydrate 0.3 0.3 0.3 0.3 0.3 Polysorbate 80 0.1 0.1 0.1 0.1 0.1 Glycerol 2.3 2.3 2.3 2.3 2.3 Edetate Sodium 0 0.001 0.01 0.05 0.1 Iron(III) nitrate 0.000001 0.000001 0.000001 0.000001 0.000001 Sodium hydroxide / dilute hydrochloric acid Moderate Moderate Moderate Moderate Moderate Water for injection Moderate Moderate Moderate Moderate Moderate pH 6.5 6.5 6.5 6.5 6.5

[0259] (2) Test methods

[0260] Test preparations 5 to 9 were filled in polyethylene containers, respectively, and these test preparations were stored at 70° C. for 4 weeks. At a time point 4 weeks after the start of storage, the concentration of sepeprost in the test preparations and the concentration of total similar substances and hydrolyzates of sepeprost were measured by high performance liquid chromatography. The total similar substance mass (%) and the hydrolyzate amount (%) were calculated as a ratio when the mass of sepeprost contained in the test preparations was set to 100%.

[0261] (3) Test results and investigation

[0262] The test results are as follows Figure 2 shown. Figure 2 A is a bar graph showing the total mass (%) of similar substances after 4 weeks of storage for each test preparation. Figure 2 B is a bar graph showing the amount of hydrolyzate (%) after 4 weeks of storage for each test preparation. Figure 2 As shown in the figure, the test preparations 8 and 9 containing 0.05% (w / v) or more of sodium edetate suppressed the generation of similar substances and hydrolyzates of sepeprost compared to the test preparation 5 not containing sodium edetate. In particular, the test preparation 9 containing 0.1% (w / v) of sodium edetate suppressed the generation of similar substances and hydrolyzates of sepeprost to about 80% compared to the test preparation 5 not containing sodium edetate. These results show that the stability of sepeprost is improved by adding more than 0.01% (w / v) of sodium edetate, especially 0.05% (w / v) or more, to the ophthalmic composition containing sepeprost.

[0263] [Test Example 3]

[0264] A preservation efficacy test was conducted on various ophthalmic compositions containing spepprostil.

[0265] (1) Preparation of test preparations 10 to 13

[0266] Test preparations 10 to 13 were prepared as shown in Table 3 by the same method as for Test preparation 1.

[0267] [Table 3]

[0268] Composition [% (w / v)] Test preparation 10 Tested preparation 11 Tested preparation 12 Tested preparation 13 Spesprost 0.003 0.003 0.003 0.003 Sodium Citrate Hydrate 0.3 0.3 0.3 0.3 Polysorbate 80 0.1 0.1 0.1 0.1 D-Mannitol 4 4 4 4 Benzalkonium chloride 0.004 0.004 0.004 0.004 Edetate Sodium 0.06 0.096 0.096 0.096 Sodium hydroxide / dilute hydrochloric acid Moderate Moderate Moderate Moderate Water for injection Moderate Moderate Moderate Moderate pH 6.5 6.0 6.5 7.0

[0269] (2) Test methods

[0270] The preservation efficacy test was conducted based on the preservation efficacy test method of the 17th edition of the Japanese Pharmacopoeia and the 8th edition of the European Pharmacopoeia. In this test, Escherichia coli (E. coli), Pseudomonas aeruginosa (P. aeruginosa), Staphylococcus aureus (S. aureus), Candida albicans (C. albicans) and Aspergillus brasiliensis (A. brasiliensis) were used as test bacteria. The concentration of the bacterial solution in the test sample containing each test preparation was 10 5 ~10 6 cfu / mL (all 5 strains) was inoculated into the test sample. 7 ~10 8 The inoculum solution was prepared in such a way that the concentration was 10 cfu / mL. 5 ~10 6 The inoculated bacterial solution was inoculated into each test sample in the manner of cfu / mL, and the samples were uniformly mixed to prepare the samples. The samples were stored at 20-25°C under light shielding, and 1 mL was collected from each sample with a micropipette at each sampling point (after 6 hours, 24 hours, 7 days, 14 days, or 28 days), and the number of viable bacteria was determined. At each sampling point, the lid of the sample solution was opened for sampling, and the lid was closed.

[0271] (3) Test results and investigation

[0272] The test results are shown in Table 4. In the test results of Table 4, the ratio (B / A) of the bacterial count (B) at the time of inoculation to the bacterial count (A) measured at the time of sampling is expressed as a common logarithmic value, for example, when it is expressed as "1", it means that the number of viable bacteria at the time of sampling is reduced to 10% of the number of inoculated bacteria.

[0273] In addition, the compliance with the preservation efficacy test was determined based on the standards of the 17th edition of the Japanese Pharmacopoeia and the 8th edition of the European Pharmacopoeia.

[0274] [Table 4]

[0275]

[0276] As shown in Table 4, the tested preparations 10 to 13 all met the preservation efficacy tests of the Japanese Pharmacopoeia and the European Pharmacopoeia and had sufficient preservation efficacy.

[0277] [Test Example 4]

[0278] In the ophthalmic composition containing spepprostil, the effect of the type of isotonic agent on bacterial proliferation was investigated.

[0279] (1) Preparation of Test Preparations 14 to 16

[0280] Test preparations 14 to 16 were prepared as shown in Table 5 by the same method as for Test preparation 1.

[0281] [Table 5]

[0282] Composition [% (w / v)] Tested preparation 14 Test preparation 15 Tested preparation 16 Spesprost 0.003 0.003 0.003 Polysorbate 80 0.1 0.1 0.1 Sodium Citrate Hydrate 0.3 0.3 0.3 Sodium chloride 0.8 - - D-Mannitol - 4 - Glycerol - - 2.3 Sodium hydroxide / dilute hydrochloric acid Moderate Moderate Moderate Water for injection Moderate Moderate Moderate pH 6.5 6.5 6.5

[0283] (2) Test methods

[0284] In this test, Aspergillus brasiliensis (A. brasiliensis) was used as the test bacteria. Test preparations 14 to 16 were placed in test tubes to prepare test samples. The concentration of the bacterial solution in the test sample containing each test preparation was 2.5×10 5 cfu / mL, the inoculated bacterial solution was inoculated into the test sample. Specifically, the inoculated bacterial solution was inoculated into the test sample so that the concentration of cfu / mL was 2.5×10 7 The inoculum solution was prepared in such a way that the concentration was 2.5×10 5 The inoculated bacterial solution was inoculated into each test sample in the form of cfu / mL and uniformly mixed to prepare a sample. These samples were stored at 20 to 25°C under light shielding, and photographs showing the appearance of each test sample 21 days after the test bacteria inoculation were taken.

[0285] (3) Test results and investigation

[0286] The test results are as follows Figure 3 shown. Figure 3 The following are photos showing the appearance of each test sample 21 days after inoculation of the test bacteria. Figure 3 As shown in the figure, the appearance of the test preparation 14 containing sodium chloride as an isotonic agent was clear 21 days after the test bacteria were inoculated, and the growth of the test bacteria (A. brasiliensis) could not be confirmed. On the other hand, in the test preparations 15 containing mannitol as an isotonic agent and the test preparation 16 containing glycerol as an isotonic agent, the presence of white floating matter was observed in the liquid 21 days after the test bacteria were inoculated, and the growth of the test bacteria (A. brasiliensis) was confirmed. This shows that ionic isotonic agents can impart a preservative effect to ophthalmic compositions.

[0287] [Test Example 5]

[0288] A preservation efficacy test was conducted on various ophthalmic compositions containing spepprostil.

[0289] (1) Preparation of Test Preparations 17 to 23

[0290] Test preparations 17 to 23 were prepared as shown in Table 6 by the same method as for Test preparation 1.

[0291] [Table 6]

[0292]

[0293] (2) Test methods

[0294] The preservation efficacy test was conducted based on the preservation efficacy test methods of the 15th edition of the Japanese Pharmacopoeia, the 33rd edition of the American Pharmacopoeia, and the 7th edition of the European Pharmacopoeia. In this test, Escherichia coli (E. coli), Pseudomonas aeruginosa (P. aeruginosa), Staphylococcus aureus (S. aureus), Candida albicans (C. albicans) and Aspergillus brasiliensis (A. brasiliensis) were used as test bacteria. The concentration of the bacterial solution in the test sample containing each test preparation was 10 5 ~10 6 cfu / mL (all 5 strains) was inoculated into the test sample. 7 ~10 8 The inoculum solution was prepared in such a way that the concentration was 10 cfu / mL. 5 ~10 6 The inoculated bacterial solution was inoculated into each test sample in the manner of cfu / mL, and the samples were uniformly mixed to prepare the samples. The samples were stored at 20-25°C under light shielding, and 1 mL was collected from each sample with a micropipette at each sampling point (after 6 hours, 24 hours, 7 days, 14 days, or 28 days), and the number of viable bacteria was determined. At each sampling point, the lid of the sample solution was opened for sampling, and the lid was closed.

[0295] (3) Test results and investigation

[0296] The test results are shown in Table 7. Table 7 shows the results of the determination of compliance with the preservation effectiveness test based on the standards of the 15th edition of the Japanese Pharmacopoeia, the 33rd edition of the American Pharmacopoeia, and the 7th edition of the European Pharmacopoeia.

[0297] [Table 7]

[0298] determination Tested preparation 17 Tested preparation 18 Tested preparation 19 Test preparation 20 Tested preparation 21 Tested preparation 22 Tested preparation 23 JP Not Compliant conform to conform to conform to conform to conform to conform to USP Not Compliant conform to conform to conform to conform to conform to conform to EP-A Not Compliant conform to conform to conform to conform to conform to conform to EP-B Not Compliant conform to conform to conform to conform to conform to conform to

[0299] As shown in Table 7, the test preparations 18 to 23 all meet the preservation efficacy tests of the Japanese Pharmacopoeia, the American Pharmacopoeia, and the European Pharmacopoeia, and have sufficient preservation efficacy. On the other hand, the test preparation 17 does not meet any of the preservation efficacy tests of the Japanese Pharmacopoeia, the American Pharmacopoeia, and the European Pharmacopoeia. Here, when the test results of the test preparation 17 and the test preparation 19 are compared, it can be seen that when benzalkonium chloride is used as a preservative and a nonionic isotonic agent is used as an isotonic agent, the preservation efficacy is sufficient, and when an ionic isotonic agent is used instead of a nonionic isotonic agent, the preservation efficacy becomes insufficient. That is, it is clear that in the presence of benzalkonium chloride, the combination of an ionic isotonic agent will reduce the preservation efficacy, and the preservation efficacy can be maintained by combining a nonionic isotonic agent.

[0300] The above results show that the stability of sepeprost can be improved by adjusting the pH to 5 to 8 and adding edetic acid or a salt thereof in an ophthalmic composition containing sepeprost. In addition, when an ionic isotonic agent is added to an ophthalmic composition containing sepeprost, the preservation efficacy can be improved. On the other hand, it is shown that the addition of an ionic isotonic agent reduces the preservation efficacy in the presence of benzalkonium chloride, but the preservation efficacy can be maintained by adding a nonionic isotonic agent.

[0301] [Test Example 6]

[0302] An ophthalmic composition containing sepeprostil was sterilized, and the stability of sepeprostil in the composition was investigated.

[0303] (1) Tested preparation

[0304] The test preparation (total amount 100 mL, pH 6.5; ingredients: 0.002 g of sepeprost, 0.3 g of sodium citrate hydrate, 0.1 g of polysorbate 800, 0.75 g of sodium chloride, 0.12 g of sodium edetate hydrate, appropriate amount of pH adjuster (sodium hydroxide or dilute hydrochloric acid), appropriate amount of water for injection) was prepared by the usual method in the art.

[0305] (2) Test methods

[0306] The prepared test preparation was sterilized by filtration or filled in a unit dose eye drop container or PFMD container (OSD bottle manufactured by Aptar) and then sterilized by gamma ray to prepare a sterile preparation. The content of sepeprost in the test preparation after sterilization was quantified by high performance liquid chromatography and its relative expressed amount (%) was calculated.

[0307] (3) Results

[0308] Table 8 shows the contents of sepeprost in the test preparations subjected to various sterilization treatments (relative amount %).

[0309] [Table 8]

[0310] Seperprostil content (relative amount %) Filter sterilization 99.5 Gamma ray sterilization 25kGy (unit dose eye drop container) 5.9 Gamma ray sterilization 25kGy (PFMD container) 6.4

[0311] According to the test results, it was confirmed that the content of sepeprost was reduced in the preparation subjected to gamma ray sterilization. On the other hand, it was confirmed that the reduction in the content of sepeprost was effectively suppressed in the preparation subjected to filter sterilization. This result shows that the ophthalmic composition of the present invention can further maintain high storage stability in the sterilized preparation by performing filter sterilization.

[0312] [Preparation Example]

[0313] Representative preparation examples using the ophthalmic composition of the present invention are shown below, but the present invention is not limited to these preparation examples. It should be noted that the amount (% (w / v)) of each component in the preparation examples below is the content (g) in 100 mL of the ophthalmic composition.

[0314] [Table 9]

[0315] Preparation Examples 1 2 3 4 5 6 Spesprost 0.002 0.002 0.002 0.002 0.002 0.002 Polysorbate 80 0.05 0.1 0.2 0.05 0.1 0.2 Sodium Citrate Hydrate 0.1 0.1 0.1 0.3 0.3 0.3 Sodium chloride 0.75 0.75 0.75 0.75 0.75 0.75 D-Mannitol - - - - - - Propylene glycol - - - - - - Glycerol - - - - - - Benzalkonium chloride - - - - - - Edetate Sodium 0.05 0.05 0.05 0.05 0.05 0.05 pH Adjusters qs qs qs qs qs qs water qs qs qs qs qs qs pH 6.0 6.0 6.0 6.0 6.0 6.0

[0316] [Table 10]

[0317] Preparation Examples 7 8 9 10 11 12 Spesprost 0.002 0.002 0.002 0.002 0.002 0.002 Polysorbate 80 0.05 0.1 0.2 0.05 0.1 0.2 Sodium Citrate Hydrate 0.1 0.1 0.1 0.3 0.3 0.3 Sodium chloride 0.75 0.75 0.75 0.75 0.75 0.75 D-Mannitol - - - - - - Propylene glycol - - - - - - Glycerol - - - - - - Benzalkonium chloride - - - - - - Edetate Sodium 0.12 0.12 0.12 0.12 0.12 0.12 pH Adjusters qs qs qs qs qs qs water qs qs qs qs qs qs pH 6.5 6.5 6.5 6.5 6.5 6.5

[0318] [Table 11]

[0319] Preparation Examples 13 14 15 16 17 18 Spesprost 0.002 0.002 0.002 0.002 0.002 0.002 Polysorbate 80 0.05 0.1 0.2 0.05 0.1 0.2 Sodium Citrate Hydrate 0.1 0.1 0.1 0.3 0.3 0.3 Sodium chloride 0.1 0.1 0.1 0.1 0.1 0.1 D-Mannitol - - - - - - Propylene glycol - - - - - - Glycerol - - - - - - Benzalkonium chloride - - - - - - Edetate Sodium 0.12 0.12 0.12 0.12 0.12 0.12 pH Adjusters qs qs qs qs qs qs water qs qs qs qs qs qs pH 7.0 7.0 7.0 7.0 7.0 7.0

[0320] [Table 12]

[0321] Preparation Examples 19 20 21 22 23 24 Spesprost 0.002 0.002 0.002 0.002 0.002 0.002 Polysorbate 80 0.05 0.1 0.2 0.05 0.1 0.2 Sodium Citrate Hydrate 0.3 0.3 0.3 0.1 0.1 0.1 Sodium chloride - - - - - - D-Mannitol 4 4 4 4 4 4 Propylene glycol - - - - - - Glycerol - - - - - - Benzalkonium chloride 0.005 0.005 0.005 0.005 0.005 0.005 Edetate Sodium 0.12 0.12 0.12 0.12 0.12 0.12 pH Adjusters qs qs qs qs qs qs water qs qs qs qs qs qs pH 6.5 6.5 6.5 6.5 6.5 6.5

[0322] [Table 13]

[0323] Preparation Examples 25 26 27 28 29 30 Spesprost 0.002 0.002 0.002 0.002 0.002 0.002 Polysorbate 80 0.05 0.1 0.2 0.05 0.1 0.2 Sodium Citrate Hydrate 0.3 0.3 0.3 0.1 0.1 0.1 Sodium chloride - - - - - - D-Mannitol 2 2 2 2 2 2 Propylene glycol - - - - - - Glycerol - - - - - - Benzalkonium chloride 0.005 0.005 0.005 0.005 0.005 0.005 Edetate Sodium 0.05 0.05 0.05 0.05 0.05 0.05 pH Adjusters qs qs qs qs qs qs water qs qs qs qs qs qs pH 6.0 6.0 6.0 6.0 6.0 6.0

[0324] [Table 14]

[0325] Preparation Examples 31 32 33 34 35 36 Spesprost 0.002 0.002 0.002 0.002 0.002 0.002 Polysorbate 80 0.05 0.1 0.2 0.05 0.1 0.2 Sodium Citrate Hydrate 0.3 0.3 0.3 0.1 0.1 0.1 Sodium chloride - - - - - - D-Mannitol Propylene glycol 2 2 2 2 2 2 Glycerol - - - - - - Benzalkonium chloride 0.005 0.005 0.005 0.005 0.005 0.005 Edetate Sodium 0.05 0.05 0.05 0.05 0.05 0.05 pH Adjusters qs qs qs qs qs qs water qs qs qs qs qs qs pH 6.5 6.5 6.5 6.5 6.5 6.5

[0326] [Table 15]

[0327] Preparation Examples 37 38 39 40 41 42 Spesprost 0.002 0.002 0.002 0.002 0.002 0.002 Polysorbate 80 0.05 0.1 0.2 0.05 0.1 0.2 Sodium Citrate Hydrate 0.3 0.3 0.3 0.1 0.1 0.1 Sodium chloride - - - - - - D-Mannitol - - - - - - Propylene glycol - - - - - - Glycerol 2 2 2 2 2 2 Benzalkonium chloride 0.005 0.005 0.005 0.005 0.005 0.005 Edetate Sodium 0.05 0.05 0.05 0.05 0.05 0.05 pH Adjusters qs qs qs qs qs qs water qs qs qs qs qs qs pH 6.0 6.0 6.0 6.0 6.0 6.0

[0328] Industrial Applicability

[0329] According to the present invention, the stability of Spepprostil in an ophthalmic composition can be improved, and an ophthalmic composition that can maintain its stability even when exposed to high temperatures during the circulation process and storage process can be provided. In addition, in the present invention, not only the stability of Spepprostil can be maintained, but also an ophthalmic composition that can maintain the preservation efficacy by using an isotonic agent of an appropriate type can be provided. In addition, in the present invention, by selecting a sterilization method for an ophthalmic composition containing Spepprostil, an ophthalmic composition that can maintain a higher preservation stability of Spepprostil in an ophthalmic composition can be provided.

Claims

1. An ophthalmic composition comprising spepprost at a concentration of 0.0001 to 0.003% (w / v) and having a pH in the range of 5 to 8. 2 . The ophthalmic composition according to claim 1 , further comprising edetic acid or a salt thereof at a concentration exceeding 0.01% (w / v).

3. The ophthalmic composition according to claim 2, wherein The concentration of edetic acid or its salt is 0.05% (w / v) or more.

4. The ophthalmic composition according to claim 2, wherein The concentration of edetic acid or its salt is 0.05 to 0.5% (w / v).

5. The ophthalmic composition according to claim 2, wherein The concentration of edetic acid or its salt is 0.05 to 0.2% (w / v). The ophthalmic composition according to any one of claims 1 to 5, wherein the pH thereof is within the range of 6 to 7. 7 . The ophthalmic composition according to claim 1 , which has a pH of 6.

5. 8 . The ophthalmic composition according to claim 1 , further comprising an isotonicity agent.

9. The ophthalmic composition according to claim 8, wherein The isotonic agent is an ionic isotonic agent. 10 . The ophthalmic composition according to claim 9 , which does not contain benzalkonium chloride. The ophthalmic composition according to claim 9 , which does not contain a preservative. 12 . The ophthalmic composition according to claim 9 , which does not contain a nonionic isotonicity agent.

13. The ophthalmic composition according to claim 8, wherein The isotonic agent is a non-ionic isotonic agent. The ophthalmic composition according to claim 13, further comprising benzalkonium chloride. The ophthalmic composition according to claim 13 or 14, which does not contain an ionic isotonic agent.

16. An ophthalmic composition comprising spepprostil at a concentration of 0.0001 to 0.003% (w / v), a nonionic isotonic agent and benzalkonium chloride, and having a pH in the range of 5 to 8. The ophthalmic composition according to claim 16 , which does not contain an ionic isotonic agent.

18. An ophthalmic composition comprising an ionic isotonic agent and spepprost at a concentration of 0.0001 to 0.003% (w / v), does not contain benzalkonium chloride, and has a pH in the range of 5 to 8. The ophthalmic composition according to claim 18 , which does not contain a preservative.

20. An ophthalmic composition comprising: 0.0001 to 0.003% (w / v) of sepeprost, Edetic acid or a salt thereof at a concentration exceeding 0.01% (w / v), and Ionic isotonic agents, The ophthalmic composition does not contain a nonionic isotonic agent and benzalkonium chloride, The pH of the ophthalmic composition is in the range of 5-8.

21. An ophthalmic composition comprising: 0.0001 to 0.003% (w / v) of sepeprost, Edetic acid or a salt thereof at a concentration exceeding 0.01% (w / v), and Nonionic isotonic agents and benzalkonium chloride, The ophthalmic composition does not contain an ionic isotonic agent, The pH of the ophthalmic composition is in the range of 5-8.

22. The ophthalmic composition according to any one of claims 12 to 17, 20 and 21, wherein The nonionic isotonic agent is at least one selected from the group consisting of mannitol, glycerol, propylene glycol, polyethylene glycol, sorbitol, trehalose, maltose and sucrose.

23. The ophthalmic composition according to claim 22, wherein The non-ionic isotonic agent is mannitol.

24. The ophthalmic composition according to any one of claims 9 to 12, 15 and 17 to 23, wherein The ionic isotonic agent is at least one selected from the group consisting of sodium chloride, potassium chloride, calcium chloride and magnesium chloride.

25. The ophthalmic composition according to claim 24, wherein The ionic isotonic agent is sodium chloride. 26 . The ophthalmic composition according to claim 1 , further comprising a buffer. 27 . The ophthalmic composition according to claim 1 , further comprising a surfactant. 28 . The ophthalmic composition according to claim 1 , which is a sterilized ophthalmic composition.

29. The ophthalmic composition according to claim 28, wherein Sterilization is filter filtration sterilization.

30. An ophthalmic composition comprising: 0.0001 to 0.003% (w / v) of sepeprost, 0.05-0.3% (w / v) concentration of polysorbate 80, Sodium citrate hydrate at a concentration of 0.1 to 0.5% (w / v), 0.05 to 0.5% (w / v) of edetate sodium, and 0.5~1% (w / v) concentration of sodium chloride, The ophthalmic composition does not contain benzalkonium chloride, The pH of the ophthalmic composition is 6-7.

31. An ophthalmic composition comprising: 0.0001 to 0.003% (w / v) of sepeprost, 0.05-0.3% (w / v) concentration of polysorbate 80, Sodium citrate hydrate at a concentration of 0.1 to 0.5% (w / v), 0.05-0.5% (w / v) concentration of edetate sodium, 1-6% (w / v) concentration of mannitol, and Benzalkonium chloride at a concentration of 0.001 to 0.0075% (w / v), The pH of the ophthalmic composition is 6-7.

32. An ophthalmic composition comprising: 0.0001 to 0.003% (w / v) of sepeprost, 0.05-0.3% (w / v) concentration of polysorbate 80, Sodium citrate hydrate at a concentration of 0.1 to 0.5% (w / v), 0.05 to 0.5% (w / v) of edetate sodium, and 0.5~1% (w / v) concentration of sodium chloride, The ophthalmic composition does not contain benzalkonium chloride, The pH of the ophthalmic composition is 6.

5.

33. An ophthalmic composition comprising: 0.0001 to 0.003% (w / v) of sepeprost, 0.05-0.3% (w / v) concentration of polysorbate 80, Sodium citrate hydrate at a concentration of 0.1 to 0.5% (w / v), 0.05-0.5% (w / v) concentration of edetate sodium, 1-6% (w / v) concentration of mannitol, and Benzalkonium chloride at a concentration of 0.001 to 0.0075% (w / v), The pH of the ophthalmic composition is 6.

5.

34. The ophthalmic composition according to any one of claims 1 to 33, wherein The concentration of sepeprost is 0.001 to 0.003% (w / v).

35. The ophthalmic composition according to any one of claims 1 to 33, wherein The concentration of sepeprost is 0.002-0.003% (w / v).

36. The ophthalmic composition according to any one of claims 1 to 33, wherein The concentration of sepeprost was 0.002% (w / v).

37. An ophthalmic composition comprising spepprostil at a concentration of 0.002 to 0.003% (w / v) and having a pH in the range of 6 to 7.

38. An ophthalmic composition comprising spepprostil at a concentration of 0.002% (w / v) and having a pH in the range of 6 to 7.

39. The ophthalmic composition according to any one of claims 1 to 38, wherein The ophthalmic composition is an eye drop. 40 . The ophthalmic composition according to any one of claims 1 to 39 , which is contained in a unit-dose eye drop container.

41. The ophthalmic composition according to any one of claims 1 to 39, contained in a multi-dose eye drop container. 42 . The ophthalmic composition according to claim 1 , which is contained in a plastic eye drop container.

43. The ophthalmic composition according to any one of claims 1 to 42, which is used for preventing or treating glaucoma or ocular hypertension.

44. A method for stabilizing spepprostil in an ophthalmic composition, wherein: In the ophthalmic composition containing spepprostil at a concentration of 0.0001 to 0.003% (w / v), the pH is adjusted to a range of 5 to 8.

45. The method of claim 44, wherein: In the ophthalmic composition containing spepprostil at a concentration of 0.002 to 0.003% (w / v), the pH is adjusted to a range of 6 to 7.

46. ​​The method according to claim 44 or 45, wherein: In the ophthalmic composition containing spepprostil at a concentration of 0.002% (w / v), the pH is adjusted to a range of 6 to 7.

Citation Information

Patent Citations

  • Bicyclic compound and use thereof for medical purposes

    WO2011013651A1

  • Bicyclic compound and use thereof for medical purposes

    WO2012102357A1

  • Method for producing bicyclic compound

    WO2018003945A1

  • MEDICAMENT COMPRISING COMBINATION OF SEPETAPROST AND Rho-KINASE INHIBITOR

    WO2019124488A1

  • Medicament comprising combination of sepetaprost and EP2 agonist

    WO2019124489A1